REFERENCES
1. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017;390:2183-93.
2. Pan Y, Suga A, Kimura I, et al. METTL23 mutation alters histone H3R17 methylation in normal-tension glaucoma. J Clin Invest. 2022;132:e153589.
3. Zhao J, Solano MM, Oldenburg CE, et al. Prevalence of normal-tension glaucoma in the Chinese population: a systematic review and meta-analysis. Am J Ophthalmol. 2019;199:101-10.
4. Shen WC, Huang BQ, Yang J. Regulatory mechanisms of retinal ganglion cell death in normal tension glaucoma and potential therapies. Neural Regen Res. 2023;18:87-93.
5. Leung DYL, Tham CC. Normal-tension glaucoma: current concepts and approaches - a review. Clin Exp Ophthalmol. 2022;50:247-59.
6. Kim JA, Lee SH, Son DH, et al. Morphologic changes in the lamina cribrosa upon intraocular pressure lowering in patients with normal tension glaucoma. Invest Ophthalmol Vis Sci. 2022;63:23.
7. Chang YH, Kang EY, Liu PK, et al. Photoreceptor manifestations of primary mitochondrial optic nerve disorders. Invest Ophthalmol Vis Sci. 2022;63:5.
8. Killer HE, Pircher A. Normal tension glaucoma: review of current understanding and mechanisms of the pathogenesis. Eye. 2018;32:924-30.
9. Harris A, Gross J, Moore N, et al. The effects of antioxidants on ocular blood flow in patients with glaucoma. Acta Ophthalmol. 2018;96:e237-41.
10. Sen S, Saxena R, Tripathi M, Vibha D, Dhiman R. Neurodegeneration in Alzheimer’s disease and glaucoma: overlaps and missing links. Eye. 2020;34:1546-53.
11. Hirooka K, Yamamoto T, Kiuchi Y. Dysfunction of axonal transport in normal-tension glaucoma: a biomarker of disease progression and a potential therapeutic target. Neural Regen Res. 2021;16:506-7.
12. Mullany S, Xiao L, Qassim A, et al. Normal-tension glaucoma is associated with cognitive impairment. Br J Ophthalmol. 2022;106:952-6.
13. Merlini E, Coleman MP, Loreto A. Mitochondrial dysfunction as a trigger of programmed axon death. Trends Neurosci. 2022;45:53-63.
14. Rowe S, MacLean CH, Shekelle PG. Preventing visual loss from chronic eye disease in primary care: scientific review. JAMA. 2004;291:1487-95.
15. Welsh JA, Goberdhan DCI, O’Driscoll L, et al; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles 2024;13:e12404.
16. Fitz NF, Wang J, Kamboh MI, Koldamova R, Lefterov I. Small nucleolar RNAs in plasma extracellular vesicles and their discriminatory power as diagnostic biomarkers of Alzheimer’s disease. Neurobiol Dis. 2021;159:105481.
17. Vergauwen G, Tulkens J, Pinheiro C, et al. Robust sequential biophysical fractionation of blood plasma to study variations in the biomolecular landscape of systemically circulating extracellular vesicles across clinical conditions. J Extracell Vesicles. 2021;10:e12122.
18. Leggio L, Paternò G, Vivarelli S, et al. Extracellular vesicles as novel diagnostic and prognostic biomarkers for Parkinson’s disease. Aging Dis. 2021;12:1494-515.
19. Mustapic M, Eitan E, Werner JK Jr, et al. Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes. Front Neurosci. 2017;11:278.
20. Hubens WHG, Krauskopf J, Beckers HJM, Kleinjans JCS, Webers CAB, Gorgels TGMF. Small RNA sequencing of aqueous humor and plasma in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2021;62:24.
21. Budnik V, Ruiz-Cañada C, Wendler F. Extracellular vesicles round off communication in the nervous system. Nat Rev Neurosci. 2016;17:160-72.
22. Dong Z, Gu H, Guo Q, et al. Profiling of serum exosome MiRNA reveals the potential of a MiRNA panel as diagnostic biomarker for Alzheimer’s disease. Mol Neurobiol. 2021;58:3084-94.
23. Shah R, Patel T, Freedman JE. Circulating extracellular vesicles in human disease. N Engl J Med. 2018;379:958-66.
24. Maacha S, Bhat AA, Jimenez L, et al. Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. Mol Cancer. 2019;18:55.
26. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.
27. Kapogiannis D, Mustapic M, Shardell MD, et al. Association of extracellular vesicle biomarkers with Alzheimer disease in the Baltimore longitudinal study of aging. JAMA Neurol. 2019;76:1340-51.
28. López-Pérez Ó, Sanz-Rubio D, Hernaiz A, et al. Cerebrospinal fluid and plasma small extracellular vesicles and miRNAs as biomarkers for prion diseases. Int J Mol Sci. 2021;22:6822.
29. Liu Y, Wang Y, Chen Y, et al. Discovery and validation of circulating Hsa-miR-210-3p as a potential biomarker for primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2019;60:2925-34.
30. McKiernan J, Donovan MJ, O’Neill V, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2016;2:882-9.
31. McKiernan J, Donovan MJ, Margolis E, et al. A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10 ng/ml at initial biopsy. Eur Urol. 2018;74:731-8.
32. Razeghinejad MR, Lee D. Managing normal tension glaucoma by lowering the intraocular pressure. Surv Ophthalmol. 2019;64:111-6.
33. Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015;67:33-41.
34. Yuan T, Huang X, Woodcock M, et al. Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep. 2016;6:19413.
35. Stein JD, Khawaja AP, Weizer JS. Glaucoma in adults-screening, diagnosis, and management: a review. JAMA. 2021;325:164-74.
36. Chuangsuwanich T, Tun TA, Braeu FA, et al. Differing associations between optic nerve head strains and visual field loss in patients with normal- and high-tension glaucoma. Ophthalmology. 2023;130:99-110.
37. Sharif NA. Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision. Neural Regen Res. 2018;13:1145-50.
38. Wareham LK, Calkins DJ. The neurovascular unit in glaucomatous neurodegeneration. Front Cell Dev Biol. 2020;8:452.
39. Artero-Castro A, Rodriguez-Jimenez FJ, Jendelova P, VanderWall KB, Meyer JS, Erceg S. Glaucoma as a neurodegenerative disease caused by intrinsic vulnerability factors. Prog Neurobiol. 2020;193:101817.
40. Mancino R, Martucci A, Cesareo M, et al. Glaucoma and Alzheimer disease: one age-related neurodegenerative disease of the brain. Curr Neuropharmacol. 2018;16:971-7.
41. Wostyn P, Van Dam D, De Deyn PP. Alzheimer’s disease and glaucoma: look-alike neurodegenerative diseases. Alzheimers Dement. 2019;15:600-1.
42. Gupta VB, Chitranshi N, den Haan J, et al. Retinal changes in Alzheimer’s disease- integrated prospects of imaging, functional and molecular advances. Prog Retin Eye Res. 2021;82:100899.
43. Verma M, Lizama BN, Chu CT. Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Transl Neurodegener. 2022;11:3.
44. Du F, Yu Q, Yan S, et al. Gain of PITRM1 peptidase in cortical neurons affords protection of mitochondrial and synaptic function in an advanced age mouse model of Alzheimer’s disease. Aging Cell. 2021;20:e13368.
45. Siena A, Yuzawa JMC, Ramos AC, et al. Neonatal rotenone administration induces psychiatric disorder-like behavior and changes in mitochondrial biogenesis and synaptic proteins in adulthood. Mol Neurobiol. 2021;58:3015-30.
46. Han S, Zhang M, Jeong YY, Margolis DJ, Cai Q. The role of mitophagy in the regulation of mitochondrial energetic status in neurons. Autophagy. 2021;17:4182-201.
47. Lu J, Sharma LK, Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 2009;19:802-15.
48. Jang SC, Crescitelli R, Cvjetkovic A, et al. Mitochondrial protein enriched extracellular vesicles discovered in human melanoma tissues can be detected in patient plasma. J Extracell Vesicles. 2019;8:1635420.
49. Mancheng AD, Ossas U. How does lncRNA regulation impact cancer metastasis. Cancer Insight. 2022;1:6.
50. Hu T, Chang S, Qi F, et al. Neural grafts containing exosomes derived from Schwann cell-like cells promote peripheral nerve regeneration in rats. Burns Trauma. 2023;11:tkad013.
51. Guo W, Cai Y, Liu X, et al. Single-exosome profiling identifies ITGB3+ and ITGAM+ exosome subpopulations as promising early diagnostic biomarkers and therapeutic targets for colorectal cancer. Research. 2023;6:0041.
52. Yu B, Xiao M, Yang F, et al. MicroRNA-431-5p encapsulated in serum extracellular vesicles as a biomarker for proliferative diabetic retinopathy. Int J Biochem Cell Biol. 2021;135:105975.
53. Yang P, Song F, Yang X, et al. Exosomal microRNA signature acts as an efficient biomarker for non-invasive diagnosis of gallbladder carcinoma. iScience. 2022;25:104816.
54. Wang YQ, Dai XD, Ran Y, et al. Circulating S100A8/A9 levels reflect intraocular inflammation in uveitis patients. Ocul Immunol Inflamm. 2020;28:133-41.
55. Gan YJ, Fang AW, Liu C, et al. Elevated plasma levels of drebrin in glaucoma patients with neurodegeneration. Front Neurosci. 2019;13:326.
56. Lee CS, Larson EB, Gibbons LE, et al. Associations between recent and established ophthalmic conditions and risk of Alzheimer’s disease. Alzheimers Dement. 2019;15:34-41.
57. Thompson AG, Gray E, Heman-Ackah SM, et al. Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers. Nat Rev Neurol. 2016;12:346-57.
